NCT04886206UnknownPhase 1
Phase I Study Testing the Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
Nantes University Hospital1 site in 1 country12 target enrollmentStarted: November 10, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Nantes University Hospital
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- number of DLT
Study Overview
Brief Summary
Patients with high risk AML non eligible for an intensive treatment and for an allogeneic transplantation will be treated with azacitidine and venetoclax. The fourth, fifth and sixth injection of azacitidine will be followed by injection of haplo-identical lymphocytes (HLI). This is a single-center phase I study to identify the dose of HLI with the most tolerable toxicity. TheBayesian continuous reassessment method (CRM) will be used
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •age ≥18 years
- •patients with de novo or secondary AML, with an unfavorable or intermediate karyotype (according to the 2017 ELN classification), or patients with relapsing AML who may receive second-line treatment
- •not candidates for intensive induction, for the following reasons
- •75 years or ≥ 18 to 74 years and at least one of the following comorbidities: PS ≥ 2 or a history of heart failure requiring treatment or LVEF ≤ 50% or chronic stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or creatinine clearance <45 ml / min; or liver damage with total bilirubin> 1.5 N or other comorbidities that the hematologist considers incompatible with intensive treatment
- •ineligible for a classic allogeneic hematopoietic stem cell transplant due to the presence of co-morbidities or too high a risk of toxicity >70 years old or at least one of the following comorbidities: PS ≥ 2 or a history of heart failure requiring treatment or LVEF ≤ 50% or chronic stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or creatinine clearance <45 ml / min; or liver damage with total bilirubin> 1.5 N
- •may receive chemotherapy with hypomethylating agents have a partially compatible (haplo-identical) major family donor (≥18 years old) eligible for lymphocyte donation.
Exclusion Criteria
- •AML with favorable karyotype (according to ELN 2017) in RC1
- •Patient with refractory or progressive AML
- •Other progressive cancer in progress
- •Karnosky index <60% or PS> 2
- •Severe hepatic function disturbance: transaminases> 5 N, hyperbilirubinemia> 30 µm / L
- •Severe infection requiring hospitalization.
- •Psychiatric illness compromising the understanding of the information or the carrying out of the study.
- •woman of childbearing potential and refusing an effective method of contraception.
- •Adult under tutorship or curatorship, under legal protection or under family authorization
- •Minor family donor (<18 years old)
Outcomes
Primary Outcomes
number of DLT
Time Frame: by day 14
Secondary Outcomes
- overall survival(1 YEAR)
- cumulative incidence of relapse(1 YEAR)
- relapse-free survival(1 YEAR)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaAMLNCT06643195Institute of Hematology & Blood Diseases Hospital, China358
Unknown
Phase 1
Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer CellsMyeloblastic LeukemiaNCT00799799University of Bologna15
Terminated
Phase 3
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CRLeukemia, Myeloid, AcuteNCT01246752University Hospital Carl Gustav Carus143
Completed
Phase 1
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7NCT01740557M.D. Anderson Cancer Center10
Terminated
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)Hematological MalignanciesNCT01139164Medical University of South Carolina78